11 January 2011 -- Biotie Therapies Corp. (“Company” or “Biotie”) has gained knowledge of the notifications regarding changes in holdings in accordance with Chapter 2, Section 9 of the Finnish Securities Markets Act, described below.
The notifications received by the Company concern the changes in holdings in the Company of UCB A/S, 5AM Partners LLC (through 5AM Ventures LLC and 5AM Co-investors LLC), Novo A/S as well as Abingworth Manangement Limited (through Abingworth Bioventures IV LP and Abingworth Bioventures IV Executives LP).
The mentioned parties are parties to a Combination Agreement entered into on 10 January 2011 among the Company, Synosia Therapeutics Holding AG (“Synosia”) as well as Synosia’s shareholders and warrant holders, described in more detail in a stock exchange release issued on 11 January 2011, under which agreement the Company will issue 161,448,371 shares to the shareholders and warrant holders of Synosia in an acquisition of the entire issued share capital and outstanding warrants of Synosia (the “Transaction”) upon completion of the Transaction. In connection with the Transaction, the Company will issue 14,912,155 to Synosia to be held in treasury and used to satisfy future potential exercise of Synosia’s options. The completion of the Transaction is subject to the necessary resolutions passed by the Company’s shareholders at the Extraordinary General Meeting of Shareholders to be held on 1 February 2011, the approval by the Finnish Financial Supervisory Authority of the prospectus in relation to the listing of the issued shares as well as certain other conditions.
According to the notifications received by the Company, none of the notifying parties currently hold shares or votes in the Company and the resulting holdings of shares and votes in the Company of the notifying parties after possible completion of the Transaction and the registration of the shares to be issued with the Finnish Trade Register would be as follows:
The number of voting rights and percentages presented above are calculated based on number of shares and voting rights to be obtained upon completion of the Transaction taking into account the treasury shares held by the Company on the date of the notification.
On the date hereof, the registered number of shares in Biotie Therapies Corp. is 176,003,931. Of these shares 14,747,084 are held by the Company and the number of outstanding shares and voting rights attached to the shares amounts thus to 161,256,847. Subject to the completion of the Transaction and subsequent to the subscription and registration of the new shares to be issued in connection with the Transaction, the aggregate number of Biotie shares will be 352,364,457. Of these shares, 29,659,239 will be held by the Company or its group companies.
Turku, 11 January 2011
Biotie Therapies Corp. Timo Veromaa President and CEO
For further information, please contact:
Virve Nurmi, Biotie Therapies Corp. tel. +358 2 274 8900 e-mail: virve.nurmi@biotie.com
DISTRIBUTION NASDAQ OMX Helsinki Ltd Main Media www.biotie.com
